Glatiramer acetate

Approved Indications

Glatiramer acetate is used to treat adults with relapsing forms of multiple sclerosis (MS). It is specifically indicated for the following conditions:

• Clinically Isolated Syndrome (CIS): This is often the first episode of neurologic symptoms that may lead to an MS diagnosis.
• Relapsing-Remitting Multiple Sclerosis (RRMS): This is the most common form of MS, where patients experience clear attacks (relapses) followed by periods of recovery.
• Active Secondary Progressive Multiple Sclerosis (SPMS): This is a stage of MS that follows an initial relapsing-remitting course, where the disease progresses more steadily but still involves active relapses.

Treatment Goals

The primary purpose of this medication is to decrease the number of flare-ups or relapses a person experiences. By reducing the frequency of these attacks, the medication may also help slow the progression of physical disability associated with the disease.

It is important to note that glatiramer acetate is not a cure for multiple sclerosis. It is also not used to treat primary progressive MS, which is a form of the disease that worsens steadily from the start without distinct relapses.

Mechanism of Action

The exact way glatiramer acetate works is not fully understood. However, researchers believe it works by modifying the immune processes that cause damage in relapsing forms of multiple sclerosis (MS).

Protecting Nerve Fibers

In people with MS, the immune system mistakenly attacks myelin, which is the protective coating that surrounds nerve fibers in the brain and spinal cord. Glatiramer acetate is composed of synthetic proteins that are chemically similar to a protein found in myelin. It is thought to work in the following ways:

• Acting as a decoy: The medication may act as a decoy for the immune system. By mimicking myelin, it may distract immune cells so they attack the drug instead of the body's own nerve coatings.
• Shifting immune cells: It may change the behavior of certain white blood cells known as T cells. It is believed to encourage the development of specific T cells that help suppress inflammation rather than promote it.
• Reducing inflammation: These modified immune cells may travel to the brain and spinal cord, where they release chemicals that help reduce the inflammatory response responsible for MS symptoms.

By altering these immune responses, glatiramer acetate helps to decrease the frequency of relapses and may help slow the accumulation of physical disability associated with the disease.

Common Side Effects

The most frequent side effects of glatiramer acetate involve reactions where the medication is injected. These may include:

• Redness, pain, swelling, or itching at the injection site
• A hard lump or mass at the injection site
• Nausea or vomiting
• Joint pain or back pain
• Flu-like symptoms, such as fever or chills

Immediate Post-Injection Reaction

Some people experience a specific group of symptoms immediately after injecting the medication. These symptoms usually last for a short time and go away on their own. They include:

• Flushing (warmth or redness of the skin)
• Chest pain or tightness
• Fast or pounding heartbeat
• Anxiety
• Shortness of breath or difficulty breathing
• Itching or skin rash

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious side effects:

• Signs of liver problems, such as yellowing of the skin or eyes, dark urine, or pain in the upper right side of the stomach
• Severe skin reactions, including permanent indentations or "dents" at the injection site (lipoatrophy) or skin death (necrosis)
• Severe allergic reactions, such as swelling of the face, lips, or throat, or difficulty swallowing
• Fainting or severe dizziness

Immediate Post-Injection Reactions

Some individuals experience a specific set of symptoms immediately after injecting glatiramer acetate. These symptoms can include flushing, chest pain, heart palpitations, anxiety, difficulty breathing, throat constriction, or a rash. These episodes usually begin within minutes of an injection, last for a short duration, and resolve on their own without further treatment. However, they can occur at any time during the course of therapy.

Chest Pain

Chest pain may occur as part of an immediate post-injection reaction or as an isolated symptom. While this pain is usually transient and does not typically indicate a heart problem, it is important to distinguish it from other serious medical conditions.

Injection Site Effects

Damage to the skin and underlying tissue can occur at the injection site. This may include:

• Lipoatrophy: The loss of fat tissue under the skin, which can cause permanent indentations or pits at the injection site.
• Skin Necrosis: Death of skin tissue, which is a rare but serious complication.

To help prevent these issues, it is important to follow proper injection techniques and rotate the areas where the medicine is injected daily.

Liver Injury

Serious liver injury, including liver failure and hepatitis, has been reported in patients using glatiramer acetate. These events can occur from days to years after starting treatment. Monitoring for symptoms such as nausea, loss of appetite, fatigue, dark urine, or yellowing of the skin and eyes (jaundice) is recommended.

Immune System Considerations

Because glatiramer acetate modifies the immune system, it may theoretically interfere with the body's ability to fight infections or monitor for abnormal cell growth. The long-term clinical significance of these effects is not fully established.

Contraindications

This medication is contraindicated for use in patients who have a known hypersensitivity to glatiramer acetate or mannitol.

Pregnancy

Information on the use of glatiramer acetate during pregnancy is limited. Animal reproduction studies have generally not shown a risk to the fetus, and available human data from observational studies have not identified a drug-associated risk of major birth defects or miscarriage. However, because there are no adequate and well-controlled studies in pregnant women, this medication should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breastfeeding

It is not known whether glatiramer acetate is excreted in human milk. While many drugs are passed into breast milk, glatiramer acetate is a mixture of synthetic polypeptides that would likely be degraded in the infant's gastrointestinal tract if ingested. Healthcare providers typically advise weighing the benefits of breastfeeding against the mother's clinical need for the drug and any potential adverse effects on the breastfed child.

Injection Form

Glatiramer acetate is available as a sterile solution for subcutaneous injection. This medication is intended to be injected into the fatty tissue layer located just under the skin.

Delivery Method

• Pre-filled Syringes: The medication is supplied in disposable syringes that are pre-filled with the solution. These are designed for ease of administration by patients or caregivers.

The solution is clear and may range from colorless to slightly yellow. Each syringe is intended for a single use only. Any remaining liquid must be discarded after the injection is performed.

FDA Approval and Indications

Glatiramer acetate was first approved by the U.S. Food and Drug Administration (FDA) in 1996. It is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults, which includes:

• Clinically isolated syndrome (CIS)
• Relapsing-remitting disease (RRMS)
• Active secondary progressive disease (SPMS)

Boxed Warning and Safety Communications

In 2024, the FDA required the addition of a Boxed Warning to the prescribing information for all glatiramer acetate injection products. This warning addresses the risk of anaphylaxis, a rare but potentially life-threatening allergic reaction. While most serious allergic reactions occur shortly after an injection, the FDA noted that these reactions can occur even after a patient has been using the medication for months or years without prior issues.

Generic Availability

The FDA has approved several generic versions of glatiramer acetate. The first generic (Glatopa) was approved in 2015 for the 20 mg/mL daily dose, followed by approval for the 40 mg/mL three-times-weekly dose in 2018. These generic versions are considered therapeutically equivalent to the brand-name drug.

Generic and Brand Options

Glatiramer acetate is available as a generic medication and under brand names such as Copaxone and Glatopa. Generic versions are typically less expensive than brand-name products. The medication is available in two different strengths: a 20 mg/mL daily injection and a 40 mg/mL injection administered three times per week. The total cost may vary based on which dosing schedule is prescribed.

Insurance and Pharmacy Factors

Most health insurance plans provide coverage for glatiramer acetate, but the out-of-pocket cost is determined by the specific plan's formulary and copay structure. Because it is an injectable medication for a chronic condition, it is often classified as a specialty drug, which may require fulfillment through a specialty pharmacy. Prices can also vary between different retail and mail-order pharmacies.

Financial Assistance

Patients may be able to reduce their costs through manufacturer-sponsored programs. These often include copay savings cards for those with commercial insurance or patient assistance programs for individuals who are uninsured or underinsured. Eligibility for these programs is usually based on income and insurance status.